The current strategy of Bionor is to further advance Vacc-4x in clinical development to develop a functional cure for HIV.
As a consequence of the new, expected ownership structure following the private placement and subsequent fully underwritten
rights offering, a new Board of Directors will be elected at the extraordinary general meeting on 9 September 2016. Accordingly,
the company's strategy will be evaluated by the new Board of Directors, which may lead to a reassessment of the company's
current short and long-term strategies. Until such further assessments have been undertaken all planning of clinical trials
is put on hold.